A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma

Immunotherapy presents a new promising approach to the treatment of disseminated lung cancer. Pemriblisumab (Kitruda®) is one of the antiPD-1 drugs registered in Russia, which is used in both the secondand, in the event of high-level PD-L1 expression (≥50%), the first-line therapy. This paper presen...

Full description

Saved in:

Bibliographic Details
Published in:	Medicinskij sovet no. 10; pp. 9 - 10
Main Authors:	K. K. Laktionov, D. I. Yudin, K. A. Sarantseva, K. P. Laktionov, V. V. Breder, E. V. Reutova
Format:	Journal Article
Language:	English
Published:	Remedium Group LLC 19-07-2018
Subjects:	non-small cell lung cancer pd-1 pd-l1 pemribrolizumab
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Immunotherapy presents a new promising approach to the treatment of disseminated lung cancer. Pemriblisumab (Kitruda®) is one of the antiPD-1 drugs registered in Russia, which is used in both the secondand, in the event of high-level PD-L1 expression (≥50%), the first-line therapy. This paper presents a clinical observation of a highly efficient pemribrolizumab treatment of a patient with metastatic adenocarcinoma.
ISSN:	2079-701X 2658-5790
DOI:	10.21518/2079-701X-2018-10-9-10